Swiss Pharma Nigeria Ltd.

Courtesy Getty Images Amid rampant buyout speculation, Mirati Therapeutics reported that it will continue its final analysis of the Phase III SAPPHIRE trial following an interim survival analysis. Friday, San Diego-based Mirati announced its commitment to completing the late-stage study assessing investigational spectrum-selective kinase inhibitor, sitravatinib, combined with the checkpoint inhibitor Opdivo, in patients with non-small cell lung cancer (NSCLC). Mirati is developing the combination treatment as a third- or fourth-line option for patients with NSCLC. Mirati officials said that they anticipate the final data analysis ought to be out by mid-2023. Mirati didn’t share additional details about the ongoing study in the announcement. The company is assessing sitravatinib in clinical trials as a treatment for patients who are resistant to prior immune checkpoint inhibitor therapy and who have progressed on platinum doublet therapy. Beyond the combination with Bristol Myers Squibb’s Opdivo, Mirati has also paired the drug with BeiGene’s checkpoint inhibitor, tislelizumab. Buyout Rumors Swirl The information comes fewer than two weeks after reports surfaced that the company was considered a takeover target. Citing unnamed sources familiar with the matter, Bloomberg reported the company garnered interest from large pharmaceutical companies. Bloomberg didn’t identify any potential buyers, and the sources said no deal was imminent. This wouldn’t be the first time Mirati has been considered a target for acquisition. Last year, rumors surfaced that Merck was considering a bid for Mirati. Mirati has a market cap of $5.1 billion. Some larger companies are reportedly interested in late-2022 bolt-on deals to complement or diversify their portfolios and pipelines. Wednesday, Horizon Therapeutics confirmed it was being courted by three large pharmaceutical companies—Johnson & Johnson, Amgen and Sanofi. Horizon Therapeutics is significantly larger than Mirati, with a market cap of more than $23 billion. GSK, which went through a split earlier this year separating its pharmaceuticals business from its consumer health business, is also rumored to be targeted for acquisition. Swiss Pharma giant Novartis, which has a long history with GSK, was reported to be interested in acquiring the U.K. company. Any such deal would be massive, as GSK has a market cap of nearly $70 billion.

Revenues increased by 384% year over year Debt ratio decreased to 7% from 75% at year-end 2021 SAN DIEGO, Nov. 7, 2022 /PRNewswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its unaudited financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Highlights Revenues were US$1,757,774 in the third quarter of 2022, up 384.2% year over year. Gross profit was US$581,742, up 124% year over year, representing a gross margin of 33.1% in the third quarter of 2022. Chun-Hsien Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "We once again delivered robust year-over-year revenue growth and continued to develop and advance the monetization of our innovative product pipeline. Looking ahead, we are recalibrating our R&D efforts to focus on the development and commercialization of our key VOC POCT and VELDONA® technologies. During the quarter, VELDONA®, our very low-dose oral interferon alpha formulation, showed its antiviral efficacy in a hamster study, and is on track to initiate Phase 2 clinical trials in Taiwan. We are also pursuing out-licensing for five Phase 2 VELONDA® candidates, with the goal of accelerating them to Phase 3 trials and commercialization. Our non-invasive and telehealth-friendly VOC POCT product pipeline delivers solutions to large and expanding markets such as STI testing and women's health. Our Ainos Flora product, which allows users to easily and discreetly test for vaginal infections and certain STIs in just minutes, is currently going through clinical studies in Taiwan. In regards to our current product line, we will broaden distribution and expand sales channels for our COVID antigen test kits in Taiwan, while ramping up sales to our existing customer base. Going forward, we will further strengthen our monetization capabilities and deliver long-term sustainable value for our shareholders." Hui-Lan Wu, Chief Financial Officer of Ainos, commented, "Year-over-year top-line growth of 384.2% was driven by strong sales of our COVID­19 Antigen Self-Test Kits during the third quarter. During the quarter, in addition to delivering strong topline growth, we reduced our debt and strengthened our balance sheet following the conversion of our convertible notes and proceeds from our public offering. As a result of these efforts, our debt ratio now stands at just 6.8%, down from 75% at year-end 2021. We will continue to ramp up our COVID antigen test business in Taiwan as we further develop and commercialize our product pipeline as scheduled." Third Quarter 2022 Financial Results Revenues Revenues increased by 384.2% to US$1,757,774 in the third quarter of 2022 from US$363,052 in the same period of 2021, driven by increased sales of the Company's COVID-19 Antigen Self-Test Kits in Taiwan. An increase in the number of COVID-19 cases in Taiwan and increased acceptance of our highly accurate self-test kit contributed to the strong performance. Cost of Revenues Cost of revenues was US$1,176,032 in the third quarter of 2022, compared with US$103,638 in the same period of 2021. Such increase was consistent with the corresponding increase in sales volume, as the Company shipped more of its COVID-19 Antigen Self-Test Kits. Gross Profit In the third quarter of 2022, gross profit was US$581,742, representing a 33.1% gross margin, compared to US$259,414, or a 71.5% gross margin a year ago. The decline in gross margin was driven by a shift in the Company's revenue mix. To align with Taiwan's infection control policy, we generated more revenue from the COVID-19 Antigen Self-Test Kit in the third quarter. In comparison, the majority of our revenue during the comparable period had been generated from sales of our COVID-19 Rapid Test Kit for use by healthcare professionals. The self-test kit accounted for all our business in the third quarter, compared to 7% in the previous quarter. Total Operating Expenses Total operating expenses increased to US$8,404,013 in the third quarter of 2022 from US$1,442,756 in the same period of 2021. The increase was mainly attributable to depreciation and amortization expenses and share-based compensation. Operating expenses excluding depreciation and amortization expenses and share-based compensation remained relatively flat, reaching US$1,118,205 in the third quarter of 2022 as compared to US$759,589 a year ago. R&D expenses increased to US$1,834,786 in the third quarter of 2022 from US$646,798 a year ago. When excluding depreciation and amortization expenses, R&D expenses increased to US$628,367 from US$401,526 over the same period. SG&A expenses increased to US$6,569,227 from US$795,958 over the same period. When excluding depreciation and amortization expenses and share-based compensation, SG&A expenses increased to US$489,838 from US$358,063 over the same period. Net Loss Net loss attributable to common stock shareholders was US$7,821,756 in the third quarter of 2022, compared with US$1,160,110 in the same period of 2021. Balance Sheet As of September 30, 2022, the Company had cash and cash equivalents of US$2,417,147 compared with US$1,751,499 as of December 31, 2021. Recent Developments On August 15, 2022, the Company announced that it had signed a Master Service Agreement with Swiss Pharmaceutical Co., Ltd. (Taiwan) ("Swiss Pharma"). According to the agreement, Swiss Pharma will test, manufacture, and package the Company's VELDONA® "GMP Clinical Batch" and "GMP Commercial Batch" product candidates for the Company's planned clinical trials under both Pharmaceutical Inspection Co-operation Scheme Good Manufacturing Practice and U.S. Food & Drug Administration Current Good Manufacturing Practice regulations. On August 24, 2022, the Company announced that it had submitted an Investigational New Drug application to the U.S. Food and Drug Administration for conducting a Phase 2 trial of its low-dose oral interferon alpha formulation, VELDONA®, for treatment of mild symptoms related to COVID-19. On September 30, 2022, the Company announced the results from its antiviral efficacy study in hamsters against the Omicron variant of SARS-CoV-2. The Company's results showed that its low-dose oral interferon alpha formulation, VELDONA®, had a therapeutic effect on lungs infected with the SARS-CoV-2 virus by regulating the immune response, thereby expediting recovery of infected animals. The Company has submitted the application documents for U.S. FDA Phase 2 clinical trials for evaluating the efficacy of VELDONA® in patients with mild COVID-19. On October 31, 2022, the Company announced that it is pursuing out-licensing opportunities for five new drug candidates for its low-dose oral interferon-alpha formulation, VELDONA®. Ainos has completed Phase 2 trials for the five new drug candidates and will work with potential partners to accelerate the candidates to Phase 3 trials and eventual commercialization of VELDONA®. About Ainos, Inc. Headquartered in San Diego, California, Ainos, Inc. (f/k/a Amarillo Biosciences, Inc.) is a diversified medtech company engaged in developing innovative medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. In addition to its proprietary therapeutics using low-dose non-injectable interferon, Ainos is committed to developing a comprehensive healthcare business portfolio encompassing medical devices and consumer healthcare products. While prioritizing the commercialization of medical devices as part of its diversification strategy, Ainos has also expanded its product portfolio to include Volatile Organic Compounds (VOC) and COVID-19 POCTs. Leveraging its patents related to VOC technologies and three issued patents for COVID-19 POCT products, the Company seeks to expedite the commercialization of its medical device pipeline, beginning with Ainos-branded COVID-19 POCT product candidates. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict," "project," 'target," "future," "seek," "likely," "strategy," "may," "should," "will," and similar references to future periods. Forward-looking statements are based only on our current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, the following: the cost of production and sales potential of the planned drug treatments announced in this press release; the impact of final approvals from the U.S. Food and Drug Administration (the "FDA") or other regulatory bodies for the planned drug treatments including the availability of emergency use authorization; the Company's limited cash and history of losses; the Company's ability to achieve profitability; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the impact of competitive or alternative products, technologies and pricing; the Company's ability to manufacture any products it develops; general economic conditions and events and the impact they may have on the Company and its potential customers, including but not limited to the impact of Covid-19; the Company's ability to obtain adequate financing in the future; the impact of promulgation and implementation of regulations by the World Health Organization, the FDA and by other governmental authorities with functions similar to those of the FDA on the Company's operations and technologies; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; the Company's ability to secure regulatory approvals for its products; and our success in managing the risks involved in the foregoing items. Readers should also review the risks and uncertainties listed in our Annual Report on Form 10-K for the year ended December 31, 2021 and other reports we the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this press release speaks only as of the date on which such statement is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investor Relations Contact ICR, LLC Robin Yang Tel: +1 646-224-6971 Email: Ainos.IR@icrinc.com Company Codes: NASDAQ-NMS:AIMD

·  集团综合收入为46.88亿欧元，按当前汇率核算增长了1.6%。[1] [1] ·  Group consolidated revenue of 4.688 billion euros, an increase of 1.6% at current exchange rate.[2] · 该收入由32.85亿欧元（+1.6%）的品牌药品和14.03亿欧元（+1.4%）的仿制药构成。[3] [3] ·  This revenue is split between 3.285 billion euros for brand-name medicines[4] (+1.6%) and 1.403 billion euros for the Generics (+1.4%).  ·  强大的全球布局：占集团收入的79%（品牌收入的96%）。 ·  A strong international presence: 79% of Group revenue (96% brand-name revenue). ·  在心脏病学和代谢领域公认的领导地位，品牌药物收入26.71亿欧元，占集团收入的57%。 ·  A proven leadership position in cardiology and metabolism with revenue from brand-name medicines of 2.671 billion euro, or 57% of Group revenue. ·  富有前景的管线：27个临床开发中项目，其中一半以上在肿瘤学领域；33个研究项目，是研发方面持续大力投入的结果（品牌药物收入的23%）。 ·  A promising pipeline with 27 projects in clinical development, more than half of which are in oncology, and 33 research projects, the result of significant and ongoing investment in R&D (23% brand-name revenue). ·  2025战略目标，旨在改善集团目前的业绩，并为患者提供新的药物。 ·  Strategic objectives for 2025, which aim to improve the Group's current performance and provide new medicines to patients. 巴黎（法国），2021年1月19日-国际独立制药集团施维雅宣布其截至2020年9月30日的2019/20财年的业绩，并介绍了其研发战略和管线。 Paris (France), January 19, 2021 – Servier, a global independent pharmaceutical group, announces its results for the 2019/20 financial year, ending September 30, 2020, and presents its Research and Development strategy and pipeline. 持续增长 Continued growth  作为一家医药健康行业的参与者，自新冠疫情伊始，施维雅集团一直保证旗下治疗药物的生产和供给，同时确保其所有员工的健康和安全。 As a healthcare player, the Servier Group has maintained the production of its treatments and their distribution to patients since the beginning of the Covid-19 crisis, while ensuring the health and safety of all its employees.  2019/20财年集团收入总额为46.88亿欧元，与上一财年相比，按实际汇率计增长1.6%，按恒定汇率计增长3.6%。品牌药物收入（32.85亿欧元）占集团收入的70%，仿制药占30%（14.03亿欧元）。 Group revenue for the 2019/20 financial year amounted to €4.688 billion, an increase of 1.6% at real exchange rates and 3.6% at constant exchange rates, compared with the previous financial year. Revenue from brand-name medicines (€3.285 billion) represents 70% of the Group revenue, and generics 30% (€1.403 billion).  营业收入增至2.8亿欧元，占集团收入的6%。税息折旧及摊销前利润（EBITDA）达到6.26亿欧元，占集团收入的13%，较上一财年有所增加，这是考虑到当前的公共卫生危机情况下，更好的控制开支并重新确定项目优先级的结果。 Operating income increased to €280 million, or 6% of Group revenue. EBITDA amounted to €626 million, or 13% of Group revenue, an increase compared with the previous year due to better control of expenses and re-prioritization of certain projects, particularly considering the current health crisis. “在新冠肺炎疫情全球危机期间，施维雅能够及时调整，在确保员工健康和安全的同时，维持药物产品的生产和分销，保障患者的使用。2019/20财年的结果符合我们的目标：品牌药物和仿制药物共同驱动销售增长，品牌药物业务受到Oncaspar®和Onivyde®等肿瘤产品业绩的有力推动。这一增长确认了集团致力于成为这一领域公认和创新参与者的雄心。“施维雅集团财务执行副总裁Pascal Lemaire评论道。“During the Covid-19 global health crisis, Servier was able to adapt to maintain the production and distribution of its medicines so that they remain available to patients, while ensuring the health and safety of its employees. Results for the 2019/20 financial year are in line with our objectives. Sales growth was driven by both brand-name and generic medicines. Growth in brand-name activities was strongly supported by the performance of oncology, including sales of Oncaspar® and Onivyde®. An increase which confirms the Group's ambition to position itself as a recognized and innovative player in this field,” comments Pascal Lemaire, Executive Vice President Finance at Servier. 肿瘤领域持续增长 Sustained growth in oncology  施维雅已将肿瘤领域作为集团优先事项之一，并从2020/21财年开始将研发预算的50%投入此领域。集团将“成为肿瘤领域公认和创新的参与者”作为目标，聚焦具有重大治疗需求的癌症类型。 Servier has made oncology one of its priorities and is devoting 50% of its R&D budget to it, starting in the 2020/21 financial year. The Group aims to become a recognized and innovative player treating certain cancers for which there is an important need. 集团于2020年6月收购生物技术公司Symphogen，2020年12月21日宣布协议收购Agios Pharmaceuticals的肿瘤业务部门，这完全符合集团战略，标志着施维雅在该领域的加速进展。 The acquisition of the biotech Symphogen, in June 2020, and the announcement on December 21, 2020 of the proposed acquisition of the oncology division of Agios Pharmaceuticals are fully in line with the Group's strategy and mark its acceleration in this area. 由全球扩张驱动的增长 Growth driven by international expansion 79%的集团收入来自在法国以外，达36.98亿欧元，比2018/19财年增长3.3%。96%的品牌药物收入来自于国际市场。 The Group generates 79% of its revenue outside France, amounting to €3.698 billion, an increase of 3.3% compared with 2018/19. Most brand-name medicines revenue, or 96%, is generated internationally. 集团一半以上的收入来自欧盟以外的地区，同比增加4.9%。 Over half of the Group’s revenue is generated outside the European Union, an increase of 4.9% over the previous year. 集团的两个主要子公司是中国和俄罗斯，收入分别为4.57亿欧元（+3.8%）和3.8亿欧元（+1.0%），继续显示出强大的增长潜力。 The Group’s two main subsidiaries are China, with revenues of €457 million (+3.8%) and Russia, with revenues of €380 million (+1.0%), which continue to show strong growth potential. 2025战略目标 Strategic objectives for 2025  集团制定了2025年战略目标，以提升业绩，继续改善治疗手段以造福患者。 The Group has set strategic objectives for 2025 to improve its performance and also to continue to invest in therapeutic progress for the benefit of patients.  为了实现这些目标，集团正在加速所有业务和组织的转型，并将数字化布局作为集团发展和绩效提升的重要杠杆。因此，今年施维雅集团成立了一个新的部门来指导数字化战略：数字、大数据和信息系统部。 To achieve these objectives, the Group is accelerating its transformation across all its activities and organization, including in the digital sector, an essential lever for the Group’s development and performance. This year, Servier has therefore set up a new department to steer the Group’s digital strategy: the Digital, Data, and Information Systems Department. 施维雅集团全球总裁Olivier Laureau指出：“集团为2025年设定了雄心勃勃的目标，旨在提升当前业绩，以研发出惠及患者的新药。因此我们加速集团所有业务部门的全球转型进程。这是为了更加致力于改善治疗手段，并确保我们的可持续性和独立身份。”Olivier Laureau, President of Servier, states: “The Group has set ambitious objectives for 2025 that aim to improve its current performance in order to develop new medicines to the benefit of patients. This is why we accelerate the Group’s global transformation dynamic, across all its business segments. This, in order to be ever more committed to therapeutic progress and to guarantee our sustainability and our independence.”  研发加快转型，促进创新 R&D accelerates its transformation to foster innovation 为了促进创新并实现集团2025年战略目标，特别是每三年推出一个新的分子实体，施维雅启动了研发业务转型规划。 A plan to transform Servier’s R&D activities was recently initiated in order to foster innovation and meet the Group’s 2025 strategic objectives, in particular that of launching a new molecular entity every three years. “为了在2025年实现集团目标，研发团队已部署了初步行动计划。计划侧重于新的创新，包括加速新药的发现和开发，以满足肿瘤学、神经病学和免疫炎症的治疗需求。这一计划同时基于通过增量研究实现与药物生命周期管理相关的创新，特别是心脏代谢领域的药物。这一转型以研发团队自公共卫生危机开始以来表现出的承诺和适应性为基础的。”施维雅研发执行副总裁Claude Bertrand评论道。In order to achieve the Group’s objectives by 2025, an initial action plan has been deployed within R&D. This plan focuses on de novo innovation, which consists of accelerating the discovery and development of new medicines to meet therapeutic needs in oncology, neurology, and immuno-inflammation. It is also based on innovation linked to medicine life-cycle management, through incremental research, particularly for medicines in the cardio-metabolic field. This transformation project is based on the commitment and adaptability demonstrated by all our teams since the beginning of the health crisis,” comments Claude Bertrand, Executive Vice President R&D at Servier. 注释/Annotations： [1]除非另有说明，否则收入与2018/19财年相比的变化按当前汇率列示。 [2]Changes in revenues compared with 2018/19 financial year are presented at current exchange rate unless otherwise stated. [3]品牌药品：由施维雅推广和分销的药品；仿制药：由施维雅集团子公司Biogaran、EGIS、Pharlab和Swipha推广和分销的药物。 [4]Brand-name medicines: medicines promoted and distributed by Servier; Generics: medicines promoted and distributed by Biogaran, EGIS, Pharlab and Swipha, subsidiaries of the Servier Group. 版权声明：本文转自施维雅，如不希望被转载的媒体或个人可与我们联系，我们将立即删除 【关于药融圈】药融圈围绕我国生物医药产业链，针对生物医药大数据、技术和资本投资、药融园(产业园)等开展系列系统性工作，促进我国生物医药产业健康发展，完善产业链，共同面对全球合作和竞争。 点分享 点点赞点在看